METHODS: We retrospectively evaluated the impact of ROSE on the length of time between patients\' EBUS/bronchoscopy procedures and discussion at sector MDT, referred to as time to treatment decision (TTD), at our institution. Additionally, we assessed impact of ROSE on number of passes (number of times nodes/masses were sampled) per procedure.
RESULTS: The mean TTD was 77.9% shorter (p = 0.001) with ROSE present than when absent. Patients who received ROSE spend 34.3% less time (p = 0.028) on lung cancer diagnostic pathway overall. There was a significant reduction in number of passes in non-malignant nodes with ROSE present (2.23) than when absent (3.14) (p < 0.001). With ROSE present there was a significantly greater number of passes at malignant sites (5.07) than non-malignant sites (2.23) (p < 0.001).
CONCLUSIONS: These findings support conclusions made in our institution\'s previous study, that utilisation of ROSE reduces TTD. ROSE also allows safe advancement through nodes with low suspicion of malignant involvement, focusing time on sampling nodes/masses of greater suspicion.
方法:我们回顾性评估了ROSE对患者EBUS/支气管镜检查与部门MDT讨论之间时间长度的影响,称为治疗决策时间(TTD),在我们的机构。此外,我们评估了ROSE对每个手术的通过次数(节点/肿块采样次数)的影响.
结果:存在ROSE时比不存在时平均TTD短77.9%(p=0.001)。接受ROSE的患者在肺癌诊断途径上花费的时间总体上减少了34.3%(p=0.028)。存在ROSE(2.23)的非恶性淋巴结的通过次数显着减少,而不存在ROSE(3.14)(p<0.001)。在存在ROSE的情况下,恶性部位(5.07)的通过次数明显多于非恶性部位(2.23)(p<0.001)。
结论:这些发现支持我们机构先前研究中得出的结论,ROSE的使用降低了TTD。ROSE还可以通过淋巴结安全推进,怀疑恶性程度低,将时间集中在更怀疑的采样节点/质量上。